Ticker Search:  Getting Started | Register | Videos | Newsletter | Partners | Login    

Basics
Biohaven Pharmaceutical Holding Company Ltd.
Biohaven Pharmaceutical Holding Co Ltd is a clinical-stage biopharmaceutical company with a portfolio of innovative, late-stage product candidates targeting neurological diseases, including rare disorders.
IPO Date: May 11, 2017
Sector: Healthcare
Industry: Biotech
Market Cap: $1.27B
Activated in VL: True
Average Daily Range
Avg Daily Range: $1.19 | 2.65%
Avg Daily Range (30 D): $0.36 | 3.55%
Avg Daily Range (90 D): $0.49 | 3.64%
Institutional Daily Volume
Avg Daily Volume: .83M
Avg Daily Volume (30 D): 4.42M
Avg Daily Volume (90 D): 2.8M
Trade Size
Avg Trade Size (Sh.): 80
Avg Trade Size (Sh.) (30 D): 113
Avg Trade Size (Sh.) (90 D): 93
Institutional Trades
Total Inst.Trades: 5,451
Avg Inst. Trade: $3.08M
Avg Inst. Trade (30 D): $2.23M
Avg Inst. Trade (90 D): $2.67M
Avg Inst. Trade Volume: .07M
Avg Inst. Trades (Per Day): 2
Market Closing Trades
Avg Closing Trade: $4.94M
Avg Closing Trade (30 D): $3.77M
Avg Closing Trade (90 D): $4.54M
Avg Closing Volume: 117.07K
   
News
Dec 2, 2025 @ 6:00 PM
Migraine Clinical Trial Pipeline Expands as 30+ Co...
Source: Delveinsight
Nov 19, 2025 @ 10:15 PM
Biohaven's Chief Accounting Officer Scooped Up 17,...
Source: Robert Izquierdo
Oct 15, 2025 @ 11:00 AM
Bexorg Raises $42.5M to Transform CNS Drug Develop...
Source: Zvonimir Vrselja, M.D., Ph.D.
Sep 29, 2025 @ 5:35 PM
10 Health Care Stocks With Whale Alerts In Today's...
Source: Benzinga Staff Writer
Sep 12, 2025 @ 2:00 PM
BHVN FINAL DEADLINE: ROSEN, LEADING TRIAL ATTORNEY...
Source: Rosen Law Firm
Financials
  TTM Q2 2025 Q1 2025
Basic EPS $-1.64 $-1.94 $-2.17
Diluted EPS $-1.64 $-1.94 $-2.17
Revenue $ M $ M $ M
Gross Profit $ $ $
Net Income / Loss $ -173.44M $ -198.15M $ -221.68M
Operating Income / Loss $ -169.38M $ -211.7M $ -221.56M
Cost of Revenue $ $ $
Net Cash Flow $ 19.39M $ 66.31M $ .15M
PE Ratio